Aska Pharmaceuticals Of Japan Enhances Pipeline And Plans To Enter Generics Market
This article was originally published in PharmAsia News
Executive Summary
Aska Pharmaceuticals President Takashi Yamaguchi expects menopausal symptoms drug Menoaid Patch will be NHI price-listed within the year. With an estimated ¥2 billion in potential sales, Aska will establish a team to prepare for next year's market launch. Aska has eight items in its pipeline, including Tavocept (dimensa), a neuropathy drug to reduce side effects of taking cancer drugs, that has shown promising results in Phase III trials in Japan. Yamaguchi also disclosed that the company plans to enter generics field with a focus on internal medicine, urology, OBGYN and otology drugs, Aska sets a ¥10 billion sales goal by fiscal year 2010. (Click here for more - Japanese language
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.